Study highlights disparities in access to new pediatric food allergy treatment, omalizumab

A study identifies racial and socioeconomic disparities in access to omalizumab, a newly FDA-approved pediatric food allergy treatment, showing that White children with private insurance are more likely to receive it than Black or Hispanic children.

This Wire brief sits within Fusion42's coverage of Health.